News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EXACT Sciences Corporation (EXAS)’ Stock Trading Halted Today; FDA Advisory Committee Meeting To Review Premarket Approval Application


3/27/2014 9:07:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Nasdaq Stock Market has halted trading of the company’s stock.

The U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel is meeting today to review the premarket approval application (PMA) for Cologuard, Exact’s stool DNA-based, non-invasive colorectal cancer screening test.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES